OFFER DEADLINE06/02/2019 00:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMENot funded by an EU programme
ORGANISATION/COMPANYIMIBIC (Maimonides Biomedical Research Institute)
IMIBIC HOSTING OFFER:
La Caixa INPhINIT INCOMING Doctoral Fellowship Programme
IMIBIC, located in Cordoba, southern Spain, is a partnership between the University of Cordoba (UCO) and the Reina Sofia University Hospital. IMIBIC offers a multidisciplinary environment focused on results-oriented research and based on precision medicine and excellence in science. IMIBIC is accredited with the Excellence distinction from the National Institute of Health Carlos III and the “HR Excellence in Research” by the EC.
The Institute is structured in 44 research groups that cooperate in the implementation of five scientific programmes. IMIBIC offers an active environment in which to conduct high-level scientific research. Regular seminars and research events offer the opportunity to meet with national and international experts covering a diverse range of topics in biomedicine. Advanced training of our PhD students is provided primarily through the Doctoral Program in Biomedicine (UCO), hosted at the IMIBIC and integrated by leading scientists from the University and the Hospital. Results from research activities are exposed yearly in the IMIBIC Young Investigator Meetings, providing an ideal environment to strengthen the skills and knowledge of young scientists and to foster translational research by bringing together experimental basic and medical sciences.
IMIBIC is young and fast growing research center. It operates in a brand new building located within the UCO Health Sciences Campus and next to the University Hospital. It hosts over 600 researchers, and offers the latest technology, equipment and laboratories to support the technical needs of the research community.
Cordoba is a medium sized city located in the hearth of Andalusia, with excellent transport connections to the main cities of Spain and both to the Mediterranean and Atlantic coasts. Rich in history and culture, Cordoba is a friendly and welcoming city, with high standard of living, making it an ideal location for international students wishing to carry out their doctoral studies in Spain.
Prof.José López-Miranda (firstname.lastname@example.org)
RESEARCH PROJECT/RESEARCH GROUP
IMIBIC group GC09: https://www.imibic.org/grupo/31
Prof. José López-Miranda is Director of the Department of Internal Medicine at the Reina Sofia University Hospital, University of Cordoba (UCO), Spain. Prof. López-Miranda is Principal Investigator of CORDIOPREV study and Director of the nutrigenomic group of the Andalusian Research Plan. In addition, Prof. José López-Miranda has participated (as principal investigator and as partner) in several research projects funded by the Spanish Ministry of Health, the Spanish Ministry of Education and Science and in 3 European Projects (FP6 LIPGENE, FP7 NUTRITECH, ERA-HDHL JPI FAME). The group is dedicated to the research excellence in nutrigenomic, biomedicine, physical activity and bioscience to facilitate translation into public health.
Our group studies the effect of dietary components on cardiovascular risk from a dual approach: nutrigenetics and their biological action on factors and mechanisms related to the development of metabolic diseases such as obesity, diabetes and metabolic syndrome. Moreover, through nutrigenetics, we investigate how common genetic variants modulate the influence of diet on markers such as postprandial metabolism, endothelial function, obesity or glucose metabolism. While investigating their biological effects, we analyze the action of nutrients on atherogenic mechanisms such as oxidative stress, inflammation, endothelial function, hemostasis, cellular signaling mechanisms.
Job position description:
Recent evidences suggest that serum lipidomic profile changes in obesity are associated with insulin resistance. Moreover, lipids play a central role in inflammation and in the progression of glucose metabolism towards diabetes. Taking into account the great diversity of lipid families, traditional clinical lipid measures quantify total amounts of triacylglycerol, cholesterol, or lipoproteins may not discern between disease and a healthy condition, as serum lipid profile is more complex. The research program will include identifying novel lipidomics biomarkers for development of type 2 diabetes, to establish relationships between whole diets and specific foods with tissue status of fatty acids as explanatory factors for diet relations with type 2 diabetes and to investigate genetic determinants of fatty acid status and metabolism which modify effects of dietary intake.
The IMIBIC Research building has laboratories for metabolomics analysis with LC-MS/MS approach in high resolution mode using a QTOF mass spectrometer for lipidomic analysis, and GC-FID for plasma FA composition determination after transesterification. The laboratories also have the latest computer facilities, including laptops and conventional computers in laboratory areas with internet connection for identification of metabolites pertaining to the different lipid families will be carried out with the aid of the METLIN MS and MS/MS databases (http://metlin.scripps.edu), the Human Metabolome Database (HMDB, version 3.5) and the LipidMaps online tool for lipids identification (http://www.lipidmaps.org).
1) At the call deadline (6th Feb 2019), applicants must be in the first four years (full-time equivalent research experience) of their research careers and not yet have been awarded a doctoral degree.
2) At the time of recruitment, candidates must comply with one of the following options:
- To have completed the studies that lead to an official university degree adapted to the European Higher Education Area awarding 300 ECTS credits, of which at least 60 ECTS credits must correspond to master level.
- To have completed a degree in university not adapted to the European Higher Education Area that gives access to doctoral studies. The verification of an equivalent level of studies to the ones mentioned above will be made by the university when the admission procedure starts.
3) Candidates must not have resided or have carried out their main activity (work, studies, etc.) in Spain for more than 12 months in the 3 years immediately prior to the call deadline (6th Feb 2019). Short stays, such as holidays, done in a country other than their country of usual residence (where they carried out their main activity), will be considered as time spent in their country of usual residence.
4) Candidates must have a demonstrable level of English (B2 or higher).
5) Only candidates whose applications meet all the requirements of the call may be accepted.
You can find this offer via the Offer Finder, available at: https://hosts.lacaixafellowships.org/finder
Select “IMIBIC – Maimonides Biomedical Research Institute to Cordoba” from the dropdown list under “RESEARCH CENTER”
You can also search the position by its title " INTERLINKING LIPIDOMIC WITH TYPE 2 DIABETES" under "SEARCH BY PROJECT TITLE / JOB POSITION TITLE".
How to Apply:
If you want to apply for an INPhINIT fellowship, click on the link below to create your personal account and fill in the on-line application form: https://www.lacaixafellowships.org/index.aspx
6 February 2019: Application deadline.
20 February 2019: Deadline for submitting the language certificate.
23 April 2019: Notification of the shortlist results.
28 and 29 May 2019: Face-to-face interviews in Barcelona.
4 June 2019: Publication of the final list of selected candidates.
4 June 2019 to 5 July 2019: Matching between the research centres – fellows.
Call for applications: